Stealth BioTherapeutics CEO discusses surprise adcomm support for ultra-rare disease drug

This week, Stealth BioTherapeutics CEO Reenie McCarthy faced a seemingly insurmountable roadblock with the company’s drug for the ultra-rare, fatal mitochondrial disease Barth syndrome. FDA …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Acon receives first FDA clearance for over-the-counter COVID-19 antigen test

Listen to the article 3 min This audio is auto-generated. Please let us know if you have feedback. Dive Brief: The Food and Drug Administration

November 10, 2023

Esperion eyes new commercial push for cholesterol-lowering drugs after big FDA label expansion

Esperion has secured major FDA label expansions for its two cholesterol-lowering drugs, a regulatory milestone that it says opens up a much bigger market and

March 26, 2024

Nature Communications publication reveals highly efficient AAV delivery of large genes using ViGeneron´s REVeRT technology – Biotech Investments

EQS-News: ViGeneron GmbH / Key word(s): Scientific publication Nature Communications publication reveals highly efficient AAV delivery of large genes using ViGeneron´s REVeRT technology 25.10.2023 /

October 26, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.